⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 1, 2026The Lancet Haematology

Global equity in paediatric cancer care

The Lancet Haematology

View at Publisher

Ask AI

Bookmark

Share

Key Points

Access to paediatric oncology treatments varies significantly across regions, impacting survival outcomes.
Health disparities in paediatric cancer care lead to poorer survival rates in low-income areas, with changes needed.
Observational analysis across multiple countries sheds light on inequitable treatment access for children with cancer.
Improvements in treatment access and health equity are essential to enhance survival rates in paediatric populations.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Analysis reveals health disparities in paediatric oncology access, highlighting the need for improved care globally.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

The Lancet Haematology (2026) studied this question.

synapsesocial.com/papers/69a76132c6e9836116a2ee73 https://doi.org/10.1016/s2352-3026(26)00042-6

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Rilzabrutinib, an oral Bruton tyrosine kinase inhibitor, in patients with warm autoimmune haemolytic anaemia: a prospective, single-arm, multicentre, phase 2b safety and clinical activity study (LUMINA 2)The Lancet Haematology · Thu,
2Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trialThe Lancet Haematology · Fri,
3Faggot cells in pericardial fluidThe Lancet Haematology · Thu,
4Venetoclax in combination with cytarabine with or without idarubicin or azacitidine in children, adolescents, and young adults with relapsed or refractory acute myeloid leukaemia (VENAML): a multicentre, phase 1 expansion studyThe Lancet Haematology · Wed,
5Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trialThe Lancet Haematology · Fri,

More from The Lancet Haematology

Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trialFri,
Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trialSun,
Expert recommendations for the conduct and appraisal of qualitative research in haematologySun,
Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts—what truly defines the disease and does it matter?Thu,
Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trialSun,